よむ、つかう、まなぶ。
06【参考資料１】Interim statement on the composition of current COVID19 vaccines World Health Organization 17 June 2022 (1 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_26922.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会（第33回 7／22）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
【参考資料１】
1
2
World Health Organization
3
Interim statement on the composition of current COVID-
4
19 vaccines
17 June 2022
5
6
7
8
Key messages:
9
・The primary goals of COVID-19 vaccination using currently licensed vaccines
10
continue to be to reduce hospitalization, severe disease and death, and to
11
protect health systems. The use of currently licensed vaccines based on the
12
index virus (i.e. the virus that was identified from the first cases of COVID-19
13
in December 2019) confers high levels of protection against severe disease
14
outcomes for all variants, including Omicron with a booster dose.
15
・There has been continuous and substantial virus evolution since SARS-CoV-2
16
emerged in late 2019 and it is likely that this evolution will continue, resulting
17
in the emergence of new variants, particularly those with changes in the spike
18
protein. The trajectory of SARS-CoV-2 evolution remains uncertain and the
19
genetic and antigenic characteristics of future variants cannot yet be predicted.
20
・Given the uncertainties of further evolution, it may be prudent to pursue an
21
additional objective of COVID-19 vaccination of achieving broader immunity
22
against circulating and emerging variants while retaining protection against
23
severe disease and death.
24
・Available data (see Annex) indicate that the inclusion of Omicron, as the most
25
antigenically distinct SARS-CoV-2 Variant of Concern, in an updated vaccine
26
composition may be beneficial if administered as a booster dose to those who
27
have already received a COVID-19 vaccination primary series.
28
29
The Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-
30
VAC) is an independent group of experts that has continued to assess the public
31
health implications of emerging SARS-CoV-2 Variants of Concern (VOC) on the
1
1
2
World Health Organization
3
Interim statement on the composition of current COVID-
4
19 vaccines
17 June 2022
5
6
7
8
Key messages:
9
・The primary goals of COVID-19 vaccination using currently licensed vaccines
10
continue to be to reduce hospitalization, severe disease and death, and to
11
protect health systems. The use of currently licensed vaccines based on the
12
index virus (i.e. the virus that was identified from the first cases of COVID-19
13
in December 2019) confers high levels of protection against severe disease
14
outcomes for all variants, including Omicron with a booster dose.
15
・There has been continuous and substantial virus evolution since SARS-CoV-2
16
emerged in late 2019 and it is likely that this evolution will continue, resulting
17
in the emergence of new variants, particularly those with changes in the spike
18
protein. The trajectory of SARS-CoV-2 evolution remains uncertain and the
19
genetic and antigenic characteristics of future variants cannot yet be predicted.
20
・Given the uncertainties of further evolution, it may be prudent to pursue an
21
additional objective of COVID-19 vaccination of achieving broader immunity
22
against circulating and emerging variants while retaining protection against
23
severe disease and death.
24
・Available data (see Annex) indicate that the inclusion of Omicron, as the most
25
antigenically distinct SARS-CoV-2 Variant of Concern, in an updated vaccine
26
composition may be beneficial if administered as a booster dose to those who
27
have already received a COVID-19 vaccination primary series.
28
29
The Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-
30
VAC) is an independent group of experts that has continued to assess the public
31
health implications of emerging SARS-CoV-2 Variants of Concern (VOC) on the
1